8-K: Cocrystal Pharma Reports 2025 Results, Advances Antivirals

Cocrystal Pharma announced its 2025 financial results and provided updates on its antiviral drug-development programs, including the ongoing Phase 1b norovirus challenge study for CDI-988.

Summary

• Reported a net loss of $8.8 million, or $0.78 per share, for the fiscal year ended December 31, 2025, a significant reduction from the $17.5 million net loss ($1.72 per share) in 2024.
• Research and development expenses decreased to $5.1 million in 2025 from $12.5 million in 2024, primarily due to the winddown of the Phase 2a influenza study.
• General and administrative expenses decreased to $4.0 million in 2025 from $5.3 million in 2024.
• Unrestricted cash stood at $7.7 million as of December 31, 2025, down from $9.9 million at the end of 2024.
• Net cash used in operating activities for 2025 was $8.2 million, a reduction from $16.5 million in 2024.
• The Phase 1b human challenge study for CDI-988, an oral antiviral candidate for norovirus, is underway at Emory University School of Medicine.
• The initial Phase 2a study for influenza candidate CC-42344 was completed, showing a favorable safety and tolerability profile, but efficacy analyses were not reported due to issues with trial conduct.
• Received a $500,000 Small Business Innovation Research Phase I award from the NIHs National Institute of Allergy and Infectious Diseases for a novel influenza A/B program.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update, driven by improved financial metrics and clinical progress for CDI-988, though tempered by the delay in CC-42344 efficacy reporting and continued cash burn.

Positives

• Significant reduction in net loss to $8.8 million in 2025 from $17.5 million in 2024.
• Reduced research and development expenses by $7.4 million (from $12.5 million to $5.1 million) and general and administrative expenses by $1.3 million (from $5.3 million to $4.0 million) year-over-year.
• Net cash used in operating activities decreased by $8.3 million (from $16.5 million to $8.2 million) in 2025, indicating improved cash management.
• The Phase 1b human challenge study for CDI-988, a first-in-class oral antiviral for norovirus, is actively underway, addressing a significant unmet medical need with a $60 billion annual global economic burden.
• CDI-988 has demonstrated superior broad-spectrum antiviral activity against multiple norovirus strains, including the prevalent GII.17 strain, and potent in vitro pan-viral activity against coronaviruses.
• Favorable Phase 1 safety and tolerability data for CDI-988 were presented, including a high-dose 1200 mg cohort.
• CC-42344 showed excellent in vitro activity against pandemic and seasonal influenza A strains, including those resistant to Tamiflu and Xofluza, and was active against the 2024 Texas H5N1 avian influenza strain.
• The initial Phase 2a study for CC-42344 reported a favorable safety and tolerability profile with no serious adverse events.
• Secured a $500,000 Small Business Innovation Research Phase I award from the NIH for a novel influenza A/B program.
• Proprietary structure-based drug discovery platform aims for faster identification of candidates with superior resistance profiles and safety characteristics.

Negatives

• Unrestricted cash decreased to $7.7 million as of December 31, 2025, from $9.9 million as of December 31, 2024.
• Efficacy analyses for the initial Phase 2a study of CC-42344 were not reported due to issues with trial conduct.
• The issues with the initial Phase 2a study for CC-42344 will prolong the development timeline for this product candidate.
• The company continues to operate at a net loss of $8.8 million for the year ended December 31, 2025.
• Common shares outstanding increased to 13.784 million as of December 31, 2025, from 10.174 million as of December 31, 2024, indicating potential dilution.

Risks

• Risks and uncertainties arising from inflation, affordability, a deteriorating labor market, the possibility of recession, and increases in interest rates.
• Uncertainty surrounding the impacts arising from imposed and threatened tariffs and developments with respect thereto.
• Wars and geopolitical conflicts, including those in the Middle East and Ukraine, impacting the Company, collaboration partners, and global economies.
• Manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions, and other business interruptions.
• Adverse impacts on the ability to obtain raw materials and test animals, as well as similar problems with vendors, CROs, and CMOs.
• Issues with the initial Phase 2a study for CC-42344, which will prolong the development timeline of this product candidate.
• The ability of CROs to recruit volunteers for, and to proceed with, clinical studies.
• The company's and collaboration partners' technology and software performing as expected.
• Financial difficulties experienced by certain partners.
• General risks arising from clinical trials and the receipt of regulatory approvals.
• Regulatory changes, including those based on initiatives and actions by the Trump Administration, which could result in delays in regulatory approvals or limit access to federal funding.
• Development of effective treatments and/or vaccines by competitors, including those financed by the U.S. government.
• Potential mutations in a virus being targeted, which may result in variants resistant to a product candidate.

Future Outlook

The company plans to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A with an additional Phase 2a study. They remain optimistic about CDI-988's viability as a treatment for coronaviruses, while currently pursuing its development for norovirus prophylaxis and treatment. The global COVID-19 therapeutics market is estimated to exceed $16 billion annually by the end of 2031.

Management Comments

• "We are delighted to report that our norovirus human challenge study evaluating efficacy and safety of CDI-988 is underway at Emory University School of Medicine. In our first cohort, healthy subjects are being inoculated with the GII.2 (Snow Mountain Virus) strain under highly controlled conditions." Sam Lee, Ph.D., President and co-CEO.
• "Norovirus remains a significant and underserved market. Developing an effective norovirus antiviral or vaccine has been challenging due to the high genetic and antigenic diversity of norovirus and lack of simple in vitro cell-based assays and animal model system." Sam Lee, Ph.D., President and co-CEO.
• "Using our proprietary structure-based drug discovery platform technology, we developed CDI-988 as a direct-acting, oral antiviral that targets a highly conserved region of the viral 3CL protease found in all known norovirus strains. As a pan-viral 3CL protease inhibitor, CDI-988 also holds potential as a broad-spectrum antiviral effective against coronaviruses." Sam Lee, Ph.D., President and co-CEO.
• "Norovirus outbreaks can strike at any time of year in semi-closed environments such as cruise ships, military settings, and healthcare and assisted-living facilities. This constant threat underscores the need for an effective oral treatment and preventive that can be deployed whenever and wherever norovirus infections emerge." James Martin, CFO and co-CEO.
• "With CDI-988, our goal is to provide an easy-to-administer, safe and effective drug to combat these unpredictable outbreaks. We believe CDI-988 represents a key value-creating opportunity for our Company and our investors." James Martin, CFO and co-CEO.

Industry Context

StockSavvy.ai notes that Cocrystal Pharma operates in the highly competitive and capital-intensive antiviral drug development sector, characterized by significant unmet needs in areas like norovirus and influenza. The company's focus on a structure-based drug discovery platform targeting conserved viral regions aligns with industry efforts to develop broad-spectrum antivirals that are less susceptible to viral mutations, a critical challenge in infectious disease. The estimated $60 billion annual global economic burden of norovirus and the $16 billion projected COVID-19 therapeutics market by 2031 highlight the substantial commercial opportunities for successful drug candidates in these areas.

Comparison to Industry Standards

• The norovirus market currently lacks approved treatments or vaccines, positioning CDI-988 as a potential first-in-class oral antiviral, which is a significant advantage compared to other infectious diseases with established treatment paradigms.
• The company's approach of targeting highly conserved regions of viral drug targets, such as the 3CL protease for norovirus and coronaviruses, is a strategy employed by leading pharmaceutical companies to develop antivirals with broad-spectrum activity and reduced resistance potential, similar to the development of broad-spectrum HIV or HCV antivirals.
• The reported in vitro activity of CC-42344 against Tamiflu and Xofluza resistant influenza strains suggests a potential competitive edge in a market where resistance to approved antivirals is a growing concern, similar to how new antibiotics are developed to combat drug-resistant bacteria.
• The $500,000 SBIR Phase I award from the NIH indicates external validation of the scientific merit of their influenza A/B program, a common funding mechanism for innovative early-stage research in the biotechnology industry.

Related Party Transactions

• Operating lease right-of-use assets included $152,000 (2025) and $42,000 (2024) to a related party.
• Current maturities of operating lease liabilities included $49,000 (2025) and $42,000 (2024) to a related party.
• Long-term operating lease liabilities included $104,000 (2025) and $0 (2024) to a related party.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced net loss and cash burn, and advancement of the norovirus program. However, dilution from increased shares outstanding and delays in the influenza program could be concerns.
• Patients: Potential future benefit from novel antiviral treatments for norovirus, influenza, and coronaviruses, addressing significant unmet medical needs.
• Employees: Reduction in employee-related expenses was a factor in lower R&D costs, which could imply workforce adjustments.
• Creditors: Improved financial efficiency (reduced loss and cash burn) could be viewed positively.
• Regulatory Authorities: Continued engagement with the FDA (Study May Proceed Letter) and UK MHRA for clinical trials.

Next Steps

• Continue the Phase 1b norovirus challenge study for CDI-988, with subsequent cohorts to be orally administered CDI-988 or placebo.
• Plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A with an additional Phase 2a study.
• Further development of CDI-988 as a prophylaxis and treatment for norovirus.
• Potentially pursue development of CDI-988 as a treatment for coronaviruses.
• Continue development of a novel, broad-spectrum lead candidate targeting the influenza A/B polymerase complex, supported by the NIH SBIR award.

Key Dates

Recommendation

The company demonstrated improved financial performance with a significantly reduced net loss and lower cash burn, which are positive indicators. The advancement of the CDI-988 norovirus program into a Phase 1b human challenge study is a key clinical milestone addressing a large unmet medical need. However, the undisclosed efficacy results and prolonged development timeline for the CC-42344 influenza program due to trial conduct issues introduce uncertainty. While the pipeline shows promise, the company remains in a clinical stage with continued cash usage and an increase in outstanding shares, suggesting a 'hold' recommendation until more definitive efficacy data emerges from its lead programs and the impact of the influenza program delay is fully assessed.

Keywords

Antiviral, Norovirus, Influenza, Coronavirus, CDI-988, CC-42344, Biotechnology, Clinical-stage, Drug development, SEC filing, Financial results, Phase 1b study, 3CL protease inhibitor, PB2 inhibitor, SARS-CoV-2